Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of RC118 combined with toripalimab or RC148 in Claudin 18.2-positive advanced solid tumors
CTR20231420Phase 2Active
- Sponsor
- RemeGen
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RC118, toripalimab, RC148 in Non-hematologic malignancy, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Started Aug 2023; status: active.
02
Drugs
RC118toripalimabRC148
03
Conditions
Non-hematologic malignancygastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20231420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231420.